Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Dhub. I'm pretty sure that IND submission is still outstanding. My rationale for that is 1. They previously RNS in May when the IND application went in and 2. Why do the placing a week before IND submission as that would have driven the SP higher. Sadly I think we are still waiting.
Lentivirus manufacturing was completed 15 November. Assuming PQ takes around 3 weeks, then that takes us to around now. Bit of a write up and the plethora of forms that whilst the basis is there, will take an update/rewrite. I think if we are 'glass full', IND next week could be possible. 'glass empty' and we are into the New Year. Can't imagine that the FDA works too hard over Christmas so largely irrelevant if filed shortly before/after Xmas in terms of approval timing following submission.
Positive news on CBR yesterday, its still very early stages but the breadth of the platform is astounding given it has the potential to treat viruses and cancers. Just imagine it going through clinical trials and being applicable to both categories, its almost a panacea, with unlimited value. I appreciate that's years away and undoubtedly a lot of hurdles to pass, but imagine!
Anyway, that aside, CAR-T PQ run must be nearing completion/completed. Documentation to go and then IND application resubmission. Not far away now.
Didn't take long for Stu to pop up again :-) The LVV remanufacturing process being a success can only be seen as a positive. That was the principle reason for the CH, which is now resolved. The only downside is the potential timing, as a PQ run required and then resubmission, although I do agree with others that the resubmission should be quicker. Whilst I dont have experience of the FDA process, I do liaise with the FCA in the UK, the financial services regulatory body, and when resubmitting cases to the FCA, you already have an allocated officer, so responses are generally quicker. I would imagine that is the same with the FDA, as the same case officer is likely to manage resubmissions.
Good spot Sprint
https://twitter.com/AuschwitzMuseum/status/1644275682510266369
Wouldnt worry about it - he spouts nonsense on his twitter account.
As it happens, Gene ID: 291962 relates to
Predicted to enable cadherin binding activity and calcium ion binding activity. Predicted to be involved in calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; cell morphogenesis; and cell-cell junction organization. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. Predicted to be part of catenin complex. Predicted to be active in adherens junction. Orthologous to human CDH7 (cadherin 7).
Spain, the world's largest olive oil producer, probably isnt too fussed by ME tensions, or Italy, the second largest for that matter.
Nice little SP bounce from yesterday... still irrelevant. CH lift and CBR... tick tock and that will have a bigger impact one way or the other.
That's not strictly true Pumpky.
It depends on class tests i.e. whether the sale of a subsidiary meets these tests. A class 1 transaction which is where the transaction is more than 25% of gross assets, profits, market cap or gross capital, it will require shareholder approval. If CBR is valuable, and given the low market cap, it will absolutely trigger a Class 1 transaction.
Anything smaller can be undertaken by the company without shareholder consent as it is deemed to be immaterial.
Dave B - absolutely. Up and down like a yo-yo. I think in part because people know there is something exciting here and within touching distance but keep getting thrown curve balls by DVS which dents investor confidence. Hold onto your hats... one day Rodney, my 4m shares might be worth something!